Comparison of drug-related problem risk assessment tools for older adults: a systematic review.

Autor: Puumalainen E; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. emmi.puumalainen@helsinki.fi., Airaksinen M; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Jalava SE; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Chen TF; Faculty of Medicine and Health, University of Sydney, Sydney, Australia., Dimitrow M; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Jazyk: angličtina
Zdroj: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2020 Mar; Vol. 76 (3), pp. 337-348. Date of Electronic Publication: 2019 Dec 10.
DOI: 10.1007/s00228-019-02796-w
Abstrakt: Purpose: This study aims to systematically review studies describing screening tools that assess the risk for drug-related problems (DRPs) in older adults (≥ 60 years). The focus of the review is to compare DRP risks listed in different tools and describe their development methods and validation.
Methods: The systematic search was conducted using evidence-based medicine, Medline Ovid, Scopus, and Web of Science databases from January 1, 1985, to April 7, 2016. Publications describing general DRP risk assessment tools for older adults written in English were included. Disease, therapy, and drug-specific tools were excluded. Outcome measures included an assessment tool's content, development methods, and validation assessment.
Results: The search produced 15 publications describing 11 DRP risk assessment tools. Three major categories of risks for DRPs included (1) patient or caregiver related risks; (2) pharmacotherapy-related risks; and (3) medication use process-related risks. Of all the risks included in the tools only 8 criteria appeared in at least 4 of the tools, problems remembering to take the medication being the most common (n=7). Validation assessments varied and content validation was the most commonly conducted (n = 9). Reliability assessment was conducted for 6 tools, most commonly by calculating internal consistency (n = 3) and inter-rater reliability (n = 2).
Conclusions: The considerable variety between the contents of the tools indicates that there is no consensus on the risk factors for DRPs that should be screened in older adults taking multiple medicines. Further research is needed to improve the accuracy and timeliness of the DRP risk assessment tools.
Databáze: MEDLINE
Externí odkaz: